Steve O’Loughlin
Equibles does not estimate personal net worth.
About Steve O’Loughlin
Earlier roles on record: CFO at Actinium Pharmaceuticals, Inc. (ATNM) until February 27, 2026. Actinium Pharmaceuticals, Inc. reported in an 8-K filed February 13, 2026 that Steve O’Loughlin resigned as Chief Financial Officer, effective February 27, 2026. The proxy statement of Actinium Pharmaceuticals, Inc. reports total compensation of $546,437 for Steve O’Loughlin in fiscal 2025, including a base salary of $445,536. Disclosed compensation is on record for 8 fiscal years.
“On February 11, 2026, Steve O'Loughlin tendered his resignation as the Chief Financial Officer of Actinium Pharmaceuticals, Inc. (the “Company”), effective as of February 27, 2026, to pursue other opportunities (the “Effective Date”).”
Affiliation history
-
Start not stated–2026-02-27
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Actinium Pharmaceuticals, Inc. (ATNM) | Former Chief Financial Officer (through February 2026) | $445,536 | $546,437 |
| 2024 | Actinium Pharmaceuticals, Inc. (ATNM) | Former Chief Financial Officer (through February 2026) | $436,800 | $581,800 |
| 2023 | Actinium Pharmaceuticals, Inc. (ATNM) | Chief Financial Officer | $420,000 | $1,490,000 |
| 2022 | Actinium Pharmaceuticals, Inc. (ATNM) | Chief Financial Officer | $400,000 | $1,476,144 |
| 2021 | Actinium Pharmaceuticals, Inc. (ATNM) | Chief Financial Officer | $370,000 | $967,034 |
| 2020 | Actinium Pharmaceuticals, Inc. (ATNM) | Chief Financial Officer | $330,000 | $818,640 |
| 2019 | Actinium Pharmaceuticals, Inc. (ATNM) | Chief Financial Officer, former Principal Financial Officer | $293,550 | $442,914 |
| 2018 | Actinium Pharmaceuticals, Inc. (ATNM) | Chief Financial Officer, former Principal Financial Officer | $285,000 | $505,552 |